Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lucid Diagnostics Inc (NQ: LUCD )

0.7990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7990
Bid (Size) 0.7990 (1)
Ask (Size) 0.8150 (188)
Prev. Close 0.7990
Today's Range 0.7990 - 0.7990
52wk Range 0.7637 - 1.721
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Penny Stocks That Could Make a Big Comeback by the End of Q2
Although penny stocks to rebound represent one of the riskiest market categories, there could be some substance here. 
Via InvestorPlace
LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q4 2023
LUCD stock results show that Lucid Diagnostics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-42.52%
-42.52%
1 Month
-26.02%
-26.02%
3 Month
-44.51%
-44.51%
6 Month
-35.04%
-35.04%
1 Year
-50.06%
-50.06%

More News

Read More
Earnings Scheduled For March 25, 2024
Via Benzinga
Earnings Preview: Lucid Diagnostics
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Preview For Lucid Diagnostics
Via Benzinga
Where Lucid Diagnostics Stands With Analysts
Via Benzinga
Preview: Lucid Diagnostics's Earnings
Via Benzinga
Lucid Diagnostics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why PAVmed Shares Are Falling Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
PAVmed and Lucid Diagnostics Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
Earnings Scheduled For November 13, 2023
Via Benzinga
A Preview Of Lucid Diagnostics's Earnings
Via Benzinga
Earnings Scheduled For August 14, 2023
Via Benzinga
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
Via Benzinga
PAVmed and Lucid Diagnostics to Provide Strategic Business Update
From PAVmed Inc.
Via Business Wire
PAVmed Partners with Novosound on Ultrasound Imaging Technology
From PAVmed Inc.
Via Business Wire
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
From Lucid Diagnostics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.